Novavax, Inc. (NASDAQ:NVAX) shares advanced 3.37% in last trading session and ended the day at $5.21. NVAX Gross Margin is 78.20% and its has a return on assets of -37.90%. Novavax, Inc. (NASDAQ:NVAX) quarterly performance is -38.56%.
On 17 Marh, Novavax, Inc. (NASDAQ:NVAX) announced that Dr. Gregory M. Glenn has been named President, Research & Development. Dr. Glenn joined Novavax as its Chief Scientific Officer in July 2010. Previously, Dr. Glenn was Chief Scientific Officer and founder of IOMAI Corporation, acquired by Intercell in 2008.
KeyCorp. (NYSE:KEY) ended the last trading day at $11.02. Company weekly volatility is calculated as 1.75% and price to cash ratio as 3.45. KeyCorp. (NYSE:KEY) showed a weekly performance of -3.59%.
On 23 March, KeyCorp. (NYSE:KEY) said that, its plans are part of an agreement with the National Community Reinvestment Coalition, which includes more than 600 community organizations that promote access to basic banking services, affordable housing and job development for working families.
On 29 March, MetLife, Inc. (NYSE:MET) shares moved down -1.26% and was closed at $42.46. MET EPS growth in last 5 year was 10.20%. MetLife, Inc. (NYSE:MET) year to date (YTD) performance is -11.15%.
MetLife, Inc. (NYSE:MET) announced that it will hold an investor conference on Thursday, Sept. 29, 2016, in New York City. Presenters will include members of MetLife’s senior management team.
CACI International Inc. (NYSE:CACI) shares moved up 5.58% in last trading session and ended the day at $105.74. CACI Gross Margin is 34.20% and its has a return on assets of 4.10%. CACI International Inc. (NYSE:CACI) quarterly performance is 11.84%.
CACI International Inc. (NYSE:CACI) will issue third quarter FY16 results at 4:15 pm Eastern Time on Wednesday, April 27, 2016. Following the release of this information, we have scheduled a conference call for Thursday, April 28, 2016 at 8:30 am Eastern Time. During the conference call, members of our senior management team will be making a brief presentation focusing on third quarter FY16, followed by a question-and-answer session to discuss our results and our future performance expectations.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) caters to the Healthcare space. Its weekly performance is -1.69%. On the last day of trading company shares ended up at $8.16. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is 6.38%.
On 24 March, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced the National Comprehensive Cancer Network (NCCN) has included ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin in its 2016 Clinical Practice Guidelines in Oncology for pancreatic adenocarcinoma.
Leave a Reply